Astrosalva Names Sarepta's Wendy Erler First Strategic Advisor
SAN MATEO – November 05, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), has appointed Wendy Erler, Senior Vice President of Patient Affairs at Sarepta Therapeutics, as the first member of its Strategic Advisory Board.
Erler to steer patient engagement and trial planning at Astrosalva
Erler will advise on patient and community engagement strategy. Her remit includes working with existing community natural history registries and bringing patient and caregiver perspectives into future clinical trial planning.
Co-founder and CEO Paul Schmidt said the order of announcements is deliberate: Erler is the first advisor named, because the company wants families to know it is being built around patients and their communities.